British Patient Capital

OMass Technologies Ltd engages in drug discovery by applying mass spectrometry to the characterization of intact protein assemblies. The company offers biotherapeutics, membrane proteins, drug binding, and purifications guiding services. In addition, OMass Technologies Ltd offers structural mass spectrometry (MS) platforms, often referred to as native mass spectrometry, for characterizing complex protein assemblies. The company assists biotechnology and pharmaceutical companies in tackling drug targets and biotherapeutics. OMass Technologies Ltd was founded in 2016 and is based in Begbroke, United Kingdom.

Oxford Quantum Circuits developing technology using the power of quantum to do things which have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies.

CloudNC Ltd. is a London-based company that specializes in developing software for designing tooling paths for numerically controlled (NC) machine tools. Founded in 2015, it offers a cloud computing service that automates the programming of computerized numerical control (CNC) milling machines, significantly enhancing efficiency in the manufacturing industry. By replacing traditional skilled human roles in metal component production, CloudNC's technology transforms CNC milling machines into user-friendly devices that can produce parts with minimal human intervention. This innovation allows clients to improve profitability per machine, streamline lead times, and enhance scalability. CloudNC aims to modernize the manufacturing sector, promoting a cleaner and more sustainable industrial revolution while addressing the industry's historical inefficiencies.

Proximie Inc., based in Bedford, Massachusetts, offers a secure software platform that facilitates virtual surgical collaboration among surgeons. By leveraging advanced telecommunication, augmented reality, artificial intelligence, and machine learning technologies, Proximie's platform enables real-time, peer-to-peer assistance during surgeries, regardless of location. This innovative approach allows surgeons to share expertise before, during, and after procedures, effectively overcoming the barriers of time and distance. Furthermore, the platform is compatible with various devices and software used in operating rooms, allowing for seamless integration and interaction. Proximie's mission is to enhance surgical knowledge and skills, enabling surgeons to refine their techniques in diverse settings, even with limited bandwidth.

IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Thought Machine Group Limited is a fintech company based in London, United Kingdom, that develops Vault, a cloud-native core banking platform designed to modernize the banking industry. Established in 2017, Thought Machine addresses the challenges posed by outdated IT infrastructures commonly found in banks, which hinder innovation and customer service. Vault is built on a microservice API architecture, allowing for flexible configuration to meet the specific requirements of various banking institutions. The platform automates data analytics and regulatory reporting while offering a range of services, including smart contracts, customer data management, and mobile application integration. By enabling banks to update their operating models and enhance their user experience, Thought Machine aims to facilitate a significant transformation in the way banking technology is utilized.

AccuRx Limited is a London-based company established in 2016 that specializes in developing text messaging software for healthcare professionals. Its platform facilitates communication between General Practitioner (GP) practices and patients, offering features such as appointment booking, patient questionnaires, online consultations, and video consultations. The Chain messaging feature allows medical practitioners to send advice, notify patients of test results, and remind them to schedule appointments. Since its inception, AccuRx has expanded its reach significantly, now serving 20% of GP practices in England. The company aims to enhance the connection between patients and their healthcare teams, improving overall communication and patient engagement.

Quantexa Limited is an information technology company based in London, specializing in entity resolution and network building technology. Founded in 2016, Quantexa offers solutions that include comprehensive customer and network views, fraud detection, compliance, anti-money laundering, and surveillance. The company's technology leverages real-time entity resolution, network analytics, and artificial intelligence to integrate diverse data sets and enhance decision-making for its clients. Quantexa serves a global clientele across various sectors, including financial services, corporate, and public institutions, and has established a strategic alliance with Accenture. The company operates internationally with offices in the UK, Brussels, New York, Boston, and Sydney.

Thought Machine Group Limited is a fintech company based in London, United Kingdom, that develops Vault, a cloud-native core banking platform designed to modernize the banking industry. Established in 2017, Thought Machine addresses the challenges posed by outdated IT infrastructures commonly found in banks, which hinder innovation and customer service. Vault is built on a microservice API architecture, allowing for flexible configuration to meet the specific requirements of various banking institutions. The platform automates data analytics and regulatory reporting while offering a range of services, including smart contracts, customer data management, and mobile application integration. By enabling banks to update their operating models and enhance their user experience, Thought Machine aims to facilitate a significant transformation in the way banking technology is utilized.

Quantexa Limited is an information technology company based in London, specializing in entity resolution and network building technology. Founded in 2016, Quantexa offers solutions that include comprehensive customer and network views, fraud detection, compliance, anti-money laundering, and surveillance. The company's technology leverages real-time entity resolution, network analytics, and artificial intelligence to integrate diverse data sets and enhance decision-making for its clients. Quantexa serves a global clientele across various sectors, including financial services, corporate, and public institutions, and has established a strategic alliance with Accenture. The company operates internationally with offices in the UK, Brussels, New York, Boston, and Sydney.